ArticleCureus2025
Long-Standing Untreated or Inadequately Treated Seropositive Rheumatoid Arthritis in the Golden Age of Disease-Modifying Antirheumatic Drugs.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease presenting with articular and extra-articular manifestations that could be related to genetic and environmental factors. Seropositive RA is marked by the presence of autoantibodies, which are associated with worse prognoses and increased risk of extra-articular manifestations, including cardiovascular diseases, lung disorders, and malignancies. Untreated RA can lead to substantial morbidity, reduced life expectancy, and poor quality of life. The development of disease-modifying antirheumatic drugs has paved the way for improving disease outcomes and reducing morbidity and complications related to disease. However, adherence to therapy remains a challenge, often influenced by drug intolerance, misconceptions, and negative beliefs regarding potential side effects and drug toxicity. Here, we report three cases presenting with devastating complications due to long-standing untreated or inadequately treated seropositive RA. This emphasizes the huge disease burden and poor quality of life as part of the natural course and progression of untreated RA. Comprehensive patient education on the disease course, treatment benefits, and potential side effects is essential to enhance adherence and facilitate shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.